Cipla

{
  "main_header": {
    "sid": 597145,
    "name": "Cipla",
    "stock_name": "Cipla",
    "full_name": "Cipla Ltd.",
    "name_url": "stocks-analysis/cipla",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,414.65",
    "chg": 60.8,
    "chgp": "4.49%",
    "dir": 1,
    "prev_price": "1,353.85",
    "mcapval": "114,281.84 Cr",
    "mcap": "Large Cap",
    "scripcode": 500087,
    "symbol": "CIPLA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE059A01026",
    "curr_date": "Jun 22, 01:36 PM",
    "curr_time": "13:37 PM",
    "last_traded_at": "Jun 22, 01:36 PM IST",
    "bse_nse_vol": "24.47 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 22, 2026",
    "traded_date_str": "2026 06 22",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cipla-597145-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cipla Ltd Sees Sharp Open Interest Surge Amid Bullish Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-sharp-open-interest-surge-amid-bullish-market-positioning-4067499",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CiplaLtd_oi_spurts_by_underlying_4067499.png",
        "date": "2026-06-22 12:00:07",
        "description": "Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in open interest (OI) in its derivatives segment on 22 June 2026, signalling heightened market activity and shifting investor sentiment. The stock outperformed its sector peers and the broader Sensex, reflecting renewed optimism despite a recent downgrade in its Mojo Grade to Sell."
      },
      {
        "title": "16,820 Call Contracts Traded on Cipla Ltd. as Stock Edges Above Rs 1,400 Strike",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-sees-surge-in-call-option-activity-amid-bullish-market-sentiment-4067451",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CiplaLtd_most_active_stocks_calls_4067451.png",
        "date": "2026-06-22 11:00:06",
        "description": "On 22 Jun 2026, Cipla Ltd. witnessed a surge in call option activity with 16,820 contracts traded at the Rs 1,400 strike price, closely aligned with the stock’s closing price of Rs 1,400.8. This synchrony between the derivatives and cash markets highlights a focused directional stance ahead of the 30 Jun 2026 expiry."
      },
      {
        "title": "Cipla Ltd. Surges 3.43% to Day's High of Rs 1402.4 — Outperforms Sector by 3.29 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-hits-intraday-high-with-343-surge-on-22-june-2026-4067335",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CiplaLtd_priceRelatedfactors_4067335.png",
        "date": "2026-06-22 10:22:00",
        "description": "The Sensex advanced 0.57% on 22 Jun 2026, yet Cipla Ltd. outpaced the broader market with a 3.43% gain, touching an intraday high of Rs 1402.4. This 3.29 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift."
      },
      {
        "title": "Cipla Ltd. is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cipla-ltd-is-rated-sell-4067382",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CiplaLtd_mojoScore_4067382.png",
        "date": "2026-06-22 10:10:04",
        "description": "Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 June 2026, providing investors with an up-to-date view of the company's performance and outlook."
      },
      {
        "title": "P/E at 26.76 vs Industry's 34.06: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-institutional-shifts-and-sector-dynamics-4066822",
        "imagepath": "",
        "date": "2026-06-22 09:21:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Cipla Ltd’s inclusion in the Nifty 50 index underscores its stature as one of India’s leading pharmaceutical companies. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures its inclusion in numerous index-tracking funds and ETFs. Consequently, Cipla benefits from steady institutional inflows driven by passive investment strategies, which can provide a degree of price support and liquidity even amid sectoral volatility.</p>\n                <p>However, index membership also brings heightened scrutiny and expectations. As a large-cap stock with a market capitalisation of approximately ₹1,09,370 crores, Cipla is often viewed as a bellwether for the Pharmaceu..."
      },
      {
        "title": "P/E at 26.86 vs Industry's 33.88: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-institutional-shifts-and-sector-dynamics-4062814",
        "imagepath": "",
        "date": "2026-06-19 09:21:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> at 26.86 stands approximately 20.7% below the sector average of 33.88. This discount suggests the market is pricing in either a relative earnings risk or a subdued growth outlook compared to peers. In an industry where many stocks command premium valuations due to robust innovation pipelines and steady demand, <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s lower multiple could reflect concerns over competitive pressures or margin sustainability. Yet, this valuation gap also raises the question of whether the stock is undervalued rel..."
      },
      {
        "title": "P/E at 26.64 vs Industry's 33.60: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amid-institutional-shifts-and-sector-dynamics-4060674",
        "imagepath": "",
        "date": "2026-06-18 09:21:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E of 26.64, which is approximately 20.7% below the Pharmaceuticals &amp; Biotechnology industry average of 33.60. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or a perceived risk premium relative to peers. The sector’s elevated P/E reflects optimism around innovation and growth prospects, but <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> appears to be valued more conservatively. This valuation gap raises the question <a href=\"https://www.marketsmojo.com/stocks-analysi..."
      },
      {
        "title": "P/E at 27.13 vs Industry's 33.60: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-challenges-amidst-nifty-50-membership-and-sector-dynamics-4058479",
        "imagepath": "",
        "date": "2026-06-17 09:21:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E multiple of 27.13, which is approximately 19.3% lower than the Pharmaceuticals & Biotechnology industry average of 33.60. This discount suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives higher risks relative to its peers. The valuation gap is significant given the sector’s generally positive earnings environment, with 19 out of 35 stocks reporting positive results recently. Investors might wonder <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"ctx\">what is the current rating for Cipla Ltd. given this valua..."
      },
      {
        "title": "P/E at 27.31 vs Industry's 33.60: What the Data Shows for Cipla Ltd.",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cipla-ltd-navigating-nifty-50-membership-amidst-mixed-performance-and-institutional-shifts-4055530",
        "imagepath": "",
        "date": "2026-06-16 09:20:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a> trades at a P/E of 27.31, which is approximately 18.7% below the sector average of 33.60. This valuation gap suggests the market is pricing in either a more cautious outlook on Cipla’s earnings growth or reflecting recent performance challenges. The discount is significant given the sector’s generally elevated valuations, driven by robust demand for pharmaceutical innovation and biotechnology advances. <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" class=\"stk\">Cipla Ltd.</a>’s valuation thus invites scrutiny — <a href=\"https://www.marketsmojo.com/stocks-analysis/cipla-597145-0\" c..."
      }
    ],
    "total": 1085,
    "sid": "597145",
    "stock_news_url": "https://www.marketsmojo.com/news/cipla-597145"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "18-Jun-2026",
      "details": "Newspaper advertisement titled Notice to shareholders for transfer of shares to the Investor Education and Protection Fund",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "16-Jun-2026",
      "details": "Appointment of Mr Shivam Puri as the CEO - One India Business and a member of the Management Council designated as a Senior Management Personnel of Company w.e.f 1st July 2026",
      "source": "BSE"
    },
    {
      "caption": "Grant Of Stock Options And The Employee Stock Appreciation Rights",
      "datetime": "16-Jun-2026",
      "details": "Grant of Stock Options and Employee Stock Appreciation Rights (ESARs)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has declared <strong>650%</strong> dividend, ex-date: 05 Jun 26",
          "dt": "2026-06-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cipla Ltd. has announced <strong>3:2</strong> bonus issue, ex-date: 24 Apr 06",
          "dt": "2006-04-24",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cipla Ltd Sees Sharp Open Interest Surge Amid Bullish Market Positioning

2026-06-22 12:00:07

Cipla Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in open interest (OI) in its derivatives segment on 22 June 2026, signalling heightened market activity and shifting investor sentiment. The stock outperformed its sector peers and the broader Sensex, reflecting renewed optimism despite a recent downgrade in its Mojo Grade to Sell.

Read full news article

16,820 Call Contracts Traded on Cipla Ltd. as Stock Edges Above Rs 1,400 Strike

2026-06-22 11:00:06

On 22 Jun 2026, Cipla Ltd. witnessed a surge in call option activity with 16,820 contracts traded at the Rs 1,400 strike price, closely aligned with the stock’s closing price of Rs 1,400.8. This synchrony between the derivatives and cash markets highlights a focused directional stance ahead of the 30 Jun 2026 expiry.

Read full news article

Cipla Ltd. Surges 3.43% to Day's High of Rs 1402.4 — Outperforms Sector by 3.29 Percentage Points

2026-06-22 10:22:00

The Sensex advanced 0.57% on 22 Jun 2026, yet Cipla Ltd. outpaced the broader market with a 3.43% gain, touching an intraday high of Rs 1402.4. This 3.29 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Read full news article

Cipla Ltd. is Rated Sell

2026-06-22 10:10:04

Cipla Ltd. is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 June 2026, providing investors with an up-to-date view of the company's performance and outlook.

Read full news article

P/E at 26.76 vs Industry's 34.06: What the Data Shows for Cipla Ltd.

2026-06-22 09:21:05

Significance of Nifty 50 Membership

Cipla Ltd’s inclusion in the Nifty 50 index underscores its stature as one of India’s leading pharmaceutical companies. This membership not only enhances the stock’s visibility among domestic and global investors but also ensures its inclusion in numerous index-tracking funds and ETFs. Consequently, Cipla benefits from steady institutional inflows driven by passive investment strategies, which can provide a degree of price support and liquidity even amid sectoral volatility.

However, index membership also brings heightened scrutiny and expectations. As a large-cap stock with a market capitalisation of approximately ₹1,09,370 crores, Cipla is often viewed as a bellwether for the Pharmaceu...

Read full news article

P/E at 26.86 vs Industry's 33.88: What the Data Shows for Cipla Ltd.

2026-06-19 09:21:05

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Cipla Ltd. at 26.86 stands approximately 20.7% below the sector average of 33.88. This discount suggests the market is pricing in either a relative earnings risk or a subdued growth outlook compared to peers. In an industry where many stocks command premium valuations due to robust innovation pipelines and steady demand, Cipla Ltd.’s lower multiple could reflect concerns over competitive pressures or margin sustainability. Yet, this valuation gap also raises the question of whether the stock is undervalued rel...

Read full news article

P/E at 26.64 vs Industry's 33.60: What the Data Shows for Cipla Ltd.

2026-06-18 09:21:26

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. trades at a P/E of 26.64, which is approximately 20.7% below the Pharmaceuticals & Biotechnology industry average of 33.60. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or a perceived risk premium relative to peers. The sector’s elevated P/E reflects optimism around innovation and growth prospects, but Cipla Ltd. appears to be valued more conservatively. This valuation gap raises the question Read full news article

P/E at 27.13 vs Industry's 33.60: What the Data Shows for Cipla Ltd.

2026-06-17 09:21:14

Valuation Picture: Discount to Industry P/E

Cipla Ltd. trades at a P/E multiple of 27.13, which is approximately 19.3% lower than the Pharmaceuticals & Biotechnology industry average of 33.60. This discount suggests that the market is pricing in either a more cautious outlook on Cipla’s earnings growth or perceives higher risks relative to its peers. The valuation gap is significant given the sector’s generally positive earnings environment, with 19 out of 35 stocks reporting positive results recently. Investors might wonder what is the current rating for Cipla Ltd. given this valua...

Read full news article

P/E at 27.31 vs Industry's 33.60: What the Data Shows for Cipla Ltd.

2026-06-16 09:20:47

Valuation Picture: Discount Amidst Sector Premiums

Cipla Ltd. trades at a P/E of 27.31, which is approximately 18.7% below the sector average of 33.60. This valuation gap suggests the market is pricing in either a more cautious outlook on Cipla’s earnings growth or reflecting recent performance challenges. The discount is significant given the sector’s generally elevated valuations, driven by robust demand for pharmaceutical innovation and biotechnology advances. Cipla Ltd.’s valuation thus invites scrutiny — Read full news article

View All News